Navigation Links
Nuvilex, Inc. Finalizes Joint Venture Agreement for the Development of Broad Spectrum All-Natural Flu Remedies
Date:9/9/2009

CHERRY HILL, N.J., Sept. 9 /PRNewswire-FirstCall/ -- Nuvilex, Inc. (OTC Bulletin Board: NVLX), announces today that it has entered into a Joint Venture Agreement with Legacy Biotechnologies, Inc., a private company based in Tampa, Florida, to develop and market all natural remedies for symptoms of broad spectrum flu viruses.

Legacy Biotech has been heavily involved with research and development for the purpose of creating all natural remedies to help prevent and treat broad-spectrum flu-type symptoms resulting from influenza-like illnesses, including swine flu. Legacy Biotechnologies has finalized a two-step protocol that offers a unique method to help decrease the duration and severity of these symptoms that will be ready for the market within the next 60 days . As part of the Agreement, Nuvilex will share in the ongoing revenue stream derived from the sale of this product and Legacy Biotechnologies will obtain worldwide rights to certain Nuvilex intellectual property.

In addition, Legacy Biotechnologies will be working with one of the proprietary compounds previously developed by Knock-Out Technologies, Ltd., a wholly-owned subsidiary of Nuvilex. Legacy Biotechnologies will be conducting and funding specific clinical research to determine the general anti-viral capacity of the proprietary Knock-Out compound. The ultimate goal of joint venture is to allow Legacy Biotechnologies and Nuvilex to commercialize a full line of nutraceutical supplements with clinically validated anti-viral action.

"We are very excited to be joining with Legacy Biotechnology in this joint venture," stated Martin Schmieg, Chairman and Chief Executive Officer of Nuvilex, Inc. "Although they work on differing modes of action, the natural remedies from Legacy Biotechnologies and the proprietary formula from Knock-Out Technologies complement each other synergistically. This joint venture allows both companies the chance to complete a comprehensive product line of all natural anti-viral treatments for broad-spectrum flu-type symptoms in a more thorough and expeditious manner."

About Nuvilex, Inc.

Nuvilex, Inc. is an emerging healthcare consumer products company. The Company's lead products include: Last Shot Hangover Remedy(TM), a unique sugar-free, calorie-free and caffeine-free liquid formula designed to ease the symptoms of a hangover; Cinnergen(TM), which promotes a healthy glucose metabolism; Cinnechol(TM), designed to help maintain normal cholesterol levels and support normal cardiovascular function; and Infinitink (R), a permanent yet more easily removable tattoo ink. The Company's complete portfolio spans aesthetics, dermatology, environmental and nutraceutical products, all of which are designed to directly or indirectly improve human health. In March 2009, Nuvilex merged with Freedom2 Holdings, Inc., the developer of Infinitink (R). In conjunction with the merger, the Company changed its name to Nuvilex, Inc. from eFoodSafety.com. Please visit www.nuvilex.com for additional information on the Company.

Safe Harbor Statement

Statements contained in this presentation that are not strictly historical are "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. The forward-looking statements are made based on information available as of the date hereof, and the Company assumes no obligation to update such forward-looking statements. Forward-looking statements are sometimes identified by words such as "intends", "anticipates", "believes", "expects", and "hopes" and involve a number of risks and uncertainties that could cause the Company's actual results to differ materially from projected results. All parties are cautioned that such forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from those in these forward-looking statements. Such risks and uncertainties include but are not limited to demand for the Company's products and services, the planned share exchange with Freedom2 Holdings, Inc., our ability to secure additional financing, and other factors that may be more fully described in reports to shareholders and periodic filings with the Securities and Exchange Commission.

    Company Contact:

    Blair Barnes
    Senior Vice President and Chief Financial Officer
    Nuvilex, Inc.
    Ph: 856-433-6088
    Email: bbarnes@nuvilex.com

    Press Contact:

    Pat Arcand
    Arcand & Madison
    Ph: 617-576-7777
    Email: pat@am-pr.com


'/>"/>
SOURCE Nuvilex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. eFoodSafety.com, Inc. Changes Name to Nuvilex, Inc., Reflecting New Strategic Direction of Company
2. Nuvilex, Inc. Launches Spring Break Initiatives Designed to Raise Visibility Among Key Demographic Group
3. Nuvilex, Inc. Announces New Pricing for Cinnergen and Launch of dLife Advertising and Promotion Campaign
4. Nuvilex, Inc.s Marketing Partner, CK41 to Launch purEffect(TM) in May
5. Nuvilex, Inc. Announces Investor Conference Call and Open House
6. Nuvilex, Inc. Announces Monthly Investor Conference Call
7. Nuvilex, Inc. Announces Business Update Conference Call
8. Nuvilex, Inc. Sets Times and Locations for Upcoming Shareholder Meetings
9. The KonLin Letter Issues Featured Stock Update on Nuvilex, Inc. in Its September 2009 Edition
10. QUANTEL Finalizes the Acquisition of WaveLight Aesthetic GmbH
11. Independence Blue Cross Finalizes New Multi-Year Agreements with Mercy Health System and St. Mary Medical Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... , ... (PRWEB) May ... three new members of its Advisory Board. Joining the Grow ... Kusch. “All three of them embody the mission of our organization ... very fortunate to have them as we continue to expand our ...
(Date:5/24/2016)... ... May 24, 2016 , ... Physical therapy is ... repairing the musculoskeletal and neuromuscular systems of the human body without recourse to ... providing treatments for physical therapy in New York, including dynamic neuromuscular stabilization ...
(Date:5/24/2016)... ... May 24, 2016 , ... Backed by decades of experience, ... job, ensuring the best suited solution to meet regulatory requirements. Their professional staff ... lab in Istanbul. , Metroloji Okulu specializes in MadgeTech’s line of medical and ...
(Date:5/24/2016)... ... May 24, 2016 , ... Eggsurance, the first ... relaunch of its community and education hub for women considering fertility preservation, as ... create a safe and welcoming place for women to find cycle buddies, get ...
(Date:5/24/2016)... ... May 24, 2016 , ... The Radiosurgery Society (RSS), a ... is recognizing five medical residents and students for their outstanding contributions to research ... awards will be presented at the 2016 SRS/SBRT Scientific Meeting taking place June ...
Breaking Medicine News(10 mins):
(Date:5/20/2016)... 2016 ReportsnReports.com adds Global ... Devices of its online business intelligence library. This ... current state of the Titrator industry. The report ... definitions, classifications, Specifications, applications and industry chain structure. ... Raw Material Suppliers, Equipment Suppliers, Manufacturing Cost Structure, ...
(Date:5/20/2016)... 20, 2016 - Revenue ... Insulins, Growth Hormones, Recombinant Coagulation Factors and Regenerative ... This New Study Reveals Selling Opportunities and Revenue ... ,What is the future of biologics, especially ... and commercial analysis. Staying ahead in data and ...
(Date:5/20/2016)... , May 20, 2016 ... Review, H1 2016" market research report with comprehensive ... (Psoriasis Vulgaris), complete with comparative analysis at various ... action (MoA), route of administration (RoA) and molecule ... and press releases. It also reviews key players ...
Breaking Medicine Technology: